ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates

ProMIS’ PMN310 Shows Improved Safety Profile, Specificity Compared to Similar Alzheimer’s Candidates
ProMIS Neurosciences’ lead therapeutic candidate for Alzheimer’s disease, PMN310, showed an improved safety profile when directly compared to other amyloid-beta directed antibodies, according to preclinical study results. Unlike BAN2401 (Biogen, Eisai) and aducanumab (Biogen), two amyloid-beta directed antibodies both in clinical development, PMN310 did not bind to nontoxic forms of amyloid beta in the Alzheimer’s brain, displaying an

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *